相似文献
1
Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study.
J Clin Microbiol. 2001 Oct;39(10):3760-3. doi: 10.1128/JCM.39.10.3760-3763.2001.
2
Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays.
J Clin Microbiol. 1999 Apr;37(4):1210-2. doi: 10.1128/JCM.37.4.1210-1212.1999.
3
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability.
J Clin Microbiol. 2003 May;41(5):1888-93. doi: 10.1128/JCM.41.5.1888-1893.2003.
4
Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil.
J Clin Microbiol. 2007 Jun;45(6):2061-3. doi: 10.1128/JCM.00136-07. Epub 2007 Mar 28.
5
A collaborative study to establish the first National Standard for HIV-1 RNA nucleic acid amplification techniques (NAT) in Taiwan.
J Virol Methods. 2013 Aug;191(2):122-7. doi: 10.1016/j.jviromet.2013.04.002. Epub 2013 Apr 19.
6
[Comparison of NucliSens HIV-1 QT and Amplicor HIV-1 monitor 1.5 in detecting HIV-1 viral load].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Jun;21(2):177-9.
7
Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma.
J Clin Microbiol. 1999 Feb;37(2):447-9. doi: 10.1128/JCM.37.2.447-449.1999.
8
Quantification of human immunodeficiency virus-1 viral load using nucleic acid sequence-based amplification (NASBA) in north central Nigeria.
Niger J Clin Pract. 2010 Sep;13(3):284-7.
9
Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests.
J Clin Virol. 2011 Feb;50(2):119-24. doi: 10.1016/j.jcv.2010.10.017. Epub 2010 Nov 24.
10
Evaluation of the NucliSens EasyQ HIV-1 v1.1 and RealTime HIV-1 kits for quantitation of HIV-1 RNA in plasma.
J Virol Methods. 2009 Oct;161(1):7-11. doi: 10.1016/j.jviromet.2009.02.003. Epub 2009 Feb 12.
引用本文的文献
1
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease.
PLoS One. 2017 Nov 27;12(11):e0188550. doi: 10.1371/journal.pone.0188550. eCollection 2017.
2
Systemic and mucosal differences in HIV burden, immune, and therapeutic responses.
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):401-11. doi: 10.1097/QAI.0b013e31820cdfdb.
3
Quality assurance in the HIV/AIDS laboratory network of China.
Int J Epidemiol. 2010 Dec;39 Suppl 2(Suppl 2):ii72-8. doi: 10.1093/ije/dyq224.
4
Oral and systemic health correlates of HIV-1 shedding in saliva.
J Dent Res. 2010 Oct;89(10):1074-9. doi: 10.1177/0022034510375290. Epub 2010 Jul 29.
5
Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.
J Epidemiol Community Health. 2006 Sep;60(9):811-8. doi: 10.1136/jech.2005.044644.
6
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
J Infect Dis. 2006 May 1;193(9):1202-10. doi: 10.1086/500843. Epub 2006 Mar 17.
7
Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.
J Infect Dis. 2005 Nov 1;192(9):1557-65. doi: 10.1086/491742. Epub 2005 Sep 29.
8
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs.
J Infect Dis. 2003 Jul 15;188(2):209-18. doi: 10.1086/376509. Epub 2003 Jul 1.
本文引用的文献
1
Accuracy of plasma HIV RNA quantification: a multicentre study of variability.
J Med Virol. 2000 Aug;61(4):417-22. doi: 10.1002/1096-9071(200008)61:4<417::aid-jmv2>3.0.co;2-1.
2
Relationship of incremental specimen volumes and enhanced detection of human immunodeficiency virus type 1 RNA with nucleic acid amplification technology.
J Clin Microbiol. 2000 Jan;38(1):85-9. doi: 10.1128/JCM.38.1.85-89.2000.
3
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.
AIDS. 1999 Nov 12;13(16):2269-79. doi: 10.1097/00002030-199911120-00009.
4
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
J Virol. 1999 Jul;73(7):5803-13. doi: 10.1128/JVI.73.7.5803-5813.1999.
5
Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment.
J Infect Dis. 1998 Dec;178(6):1803-5. doi: 10.1086/314503.
6
Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma.
J Clin Microbiol. 1998 Mar;36(3):835-9. doi: 10.1128/JCM.36.3.835-839.1998.
7
The Women's Interagency HIV Study. WIHS Collaborative Study Group.
Epidemiology. 1998 Mar;9(2):117-25.
8
Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.
J Clin Microbiol. 1998 Jan;36(1):311-4. doi: 10.1128/JCM.36.1.311-314.1998.
9
Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days.
J Infect Dis. 1997 Aug;176(2):514-7. doi: 10.1086/517278.
10
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Ann Intern Med. 1997 Jun 15;126(12):946-54. doi: 10.7326/0003-4819-126-12-199706150-00003.
Zotero 插件